Table 6 Clinical trials on ncRNAs to investigate their role in breast cancer prognosis
From: Non-coding RNAs, a double-edged sword in breast cancer prognosis
Title | Year | Country | Diagnostic, prognostic, and treatment insights | Study population | Results | Clinical trial ID |
|---|---|---|---|---|---|---|
MicroRNAs Methylation and Expression Profiling for Identification of Breast Cancer Patients at High Risk to Develop Distant Metastases | 2014–2019 | Italy | Prognosis factor | Breast Cancer Cases diagnosed from 2004 to 2014 | No results posted- Completed | NCT06555354 [409] |
Studying the Association of Genetic Variations in Long Intergenic Non-coding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population | 2021–2023 | Egypt | Possible diagnostic and prognostic aid | Histopathologically confirmed primary breast cancer patients, adult female patients between the ages of 20 to 70 years | No results posted- Completed | NCT06357689 [410] |
Investigating The Role of Key Non-coding RNA(s) in Breast Cancer Patients and Their Possible Crosstalk with Chromatin Remodeling Machinery | 2024- (ongoing) | Egypt | Diagnostic and prognostic aid | Malignant nonmetastatic female breast cancer patients; newly diagnosed breast cancer patients | No results posted- Recruiting | NCT06759714 [411] |
Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High-Risk Triple-negative Breast Cancer Patients Predicted by the Messenger RNA (mRNA)-Long Non-coding RNA (lncRNA) Signature and Validation of the Signature's Efficacy | 2016- (ongoing) | China | Predicting Recurrence risk and choosing the most appropriate chemotherapy treatment | Triple-negative breast cancer confirmed by pathology; between the ages of 18 to 70 years old and naïve to chemotherapy and hormonal treatments | No results posted- active, not recruiting | NCT02641847 [412] |
Impact of Somatic PIK3CA Mutations on Pathological Complete Response (pCR) in HER2-positive Early Breast Cancer | 2022- (ongoing) | Italy | To investigate the association of pCR and PIK3CA mutations, perform a transcriptomic analysis of coding RNAs and long non-coding RNAs | HER2-positive breast cancer patients who received neoadjuvant chemotherapy | No results posted- active, not recruiting | NCT05750693 [413] |